Viatris Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the company's revenue and growth challenges, particularly related to a failed FDA inspection at its Indore facility [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Viatris securities between August 8, 2024, and February 26, 2025, with a deadline of June 3, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and complimentary case evaluations [2]. Group 2: Allegations Against Viatris - The lawsuit claims that Viatris downplayed the seriousness of the failed FDA inspection and its consequences, leading to a false impression of the company's stability [3]. - It is alleged that Viatris underestimated the impact of the FDA inspection failure, which resulted in significant setbacks, including ongoing remediation efforts and disruptions in manufacturing and shipping key products like Lenalidomide [4]. Group 3: Financial Impact - On February 27, 2025, Viatris reported disappointing fourth-quarter and full-year 2024 financial results, along with guidance for fiscal year 2025 that reflected the expected financial effects of the FDA warning letter [5]. - Following this announcement, Viatris' stock price experienced a decline of over 15% [5].